First Cardiology Clinic, Medical School University of Athens, Hippokration Hospital, Athens, Greece.
Nephrology Department and Renal Transplantation Unit, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
J Hum Hypertens. 2018 Jul;32(7):487-493. doi: 10.1038/s41371-018-0065-y. Epub 2018 May 1.
Data regarding the prognosis of resistant hypertension (RHTN) with respect to its severity is limited. We investigated the cardiovascular risk of severe RHTN in a prospective observational study. A cohort of 1700 hypertensive patient with treated uncontrolled HTN was followed for a mean period of 3.6 ± 1.8 years. At baseline, standard clinical and laboratory workup was performed, including testing for secondary causes of RHT where applicable. Three groups were identified depending on presence of RHTN (office-based uncontrolled HTN under at least three drugs including a diuretic) and levels of office systolic blood pressure (BP): 1187 patients (70%) without RHTN, 313 (18%) with not-severe RHTN (systolic BP < 160 mmHg) and 200 (12%) with severe RHTN (systolic BP ≥ 160 mmHg). Endpoint of interest was cardiovascular morbidity set as the composite of coronary heart disease and stroke. During follow-up, incidence rates of cardiovascular events per 1000 person-years were 7.1 cases in the non-RHTN group, 12.4 cases in the not-severe RHTN group and 18 cases in the severe RHTN group. Unadjusted analysis showed that compared to uncontrolled patients without RHTN, patients with not-severe RHTN exhibited a similar risk but patients with severe RHTN had a significantly higher risk, by 2.5 times (CI: 1.28-4.73, p = 0.007). Even after multivariate adjustment for established risk factors including BP levels and isolated systolic HTN, severe RHTN remained as an independent predictor of the cardiovascular outcome (OR: 2.30, CI: 1.00-5.29, p = 0.05). In conclusion, among treated yet uncontrolled hypertensive patients, severe RHTN exhibits a significantly higher cardiovascular risk indicating the need for prompt management.
关于严重难治性高血压 (RHTN) 的预后数据有限。我们在一项前瞻性观察研究中调查了严重 RHTN 的心血管风险。一组 1700 名患有治疗后未控制的 HTN 的高血压患者的随访时间平均为 3.6±1.8 年。在基线时,进行了标准的临床和实验室检查,包括有必要时检查 RHT 的继发性原因。根据存在 RHTN(至少三种药物治疗但仍未控制的诊室血压)和诊室收缩压 (BP) 水平,将患者分为三组:1187 名患者(70%)无 RHTN、313 名患者(18%)为非严重 RHTN(收缩压<160mmHg)和 200 名患者(12%)为严重 RHTN(收缩压≥160mmHg)。感兴趣的终点是心血管发病率,定义为冠心病和中风的复合事件。随访期间,非 RHTN 组、非严重 RHTN 组和严重 RHTN 组每 1000 人年的心血管事件发生率分别为 7.1 例、12.4 例和 18 例。未调整分析显示,与无 RHTN 的未控制患者相比,非严重 RHTN 患者的风险相似,但严重 RHTN 患者的风险显著增加了 2.5 倍(CI:1.28-4.73,p=0.007)。即使在校正了包括血压水平和孤立性收缩期 HTN 在内的已确立的危险因素后,严重 RHTN 仍然是心血管结局的独立预测因素(OR:2.30,CI:1.00-5.29,p=0.05)。总之,在治疗后仍未控制的高血压患者中,严重 RHTN 显示出更高的心血管风险,表明需要及时治疗。